1-(2-chloro-1-cyclopentenyl)ethanol | 120504-81-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-chloro-1-cyclopentenyl)ethanol
• 英文别名: 1-(2-chlorocyclopenten-1-yl)ethanol
• CAS: 120504-81-6
• 化学式: C₇H₁₁ClO
• 分子量: 146.617
• InChiKey: VEGJASQIFSKIMY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(2-chloro-1-cyclopentenyl)ethanol 在 二苯基磷酸 、 三乙胺 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 28.0h， 生成 methyl 3-(4-{4-[1-(2-chloro-1-cyclopentenyl)-ethoxycarbonylamino]-3-isoxazolyl}benzylsulfanyl)propionate
  参考文献：
  名称：

  Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists

  摘要：

  A series of isoxazole derivatives were synthesized and their antagonistic activities against LPA stimulation on both LPA(1)/ CHO cells and rHSC cells were evaluated. Among them, 3 -(4-{4- [1 -(2-chloro-cyclopent-1-enyl) -ethoxycarbonylamino] -isoxazol - 3- yl}-benzylsulfanyl)-propionic acid (34) showed the most potent activities. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.024
• 作为产物：
  描述：

  2-氯环戊烯-1-甲醛 在 甲基溴化镁 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 0.5h， 以41.6%的产率得到1-(2-chloro-1-cyclopentenyl)ethanol
  参考文献：
  名称：

  Novel azole compound

  摘要：

  由公式I表示的唑类化合物： 其中环A是异噁唑等，R1是取代的或未取代的芳基团等，R2是氢原子等，R3是取代的或未取代的烷基团等，以及药用可接受的盐，可以抑制溶血磷脂酸（LPA）的生理活性，并且用于预防或治疗抑制LPA生理活性对预防或治疗有用的疾病，如涉及LPA受体的疾病。

  公开号：

  US20060194850A1

文献信息

• [EN] LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS D'ACIDE LYSOPHOSPHATIDIQUE
  申请人：INTERMUNE INC

  公开号：WO2013025733A1

  公开（公告）日：2013-02-21

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  提供了化合物、制备这种化合物的方法、包含这种化合物的药物组合物和药物，以及使用这种化合物治疗、预防或诊断与一种或多种赖氨酸磷脂酸受体相关的疾病、紊乱或状况的方法。
• Azole compound
  申请人：Ajinomoto Co., Inc.

  公开号：US07517996B2

  公开（公告）日：2009-04-14

  Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

  公式I所代表的氮唑化合物：其中环A为异噁唑等，R1为取代或未取代的芳基基团等，R2为氢原子等，R3为取代或未取代的烷基基团等，以及其药学上可接受的盐，能够抑制溶血磷脂酸（LPA）的生理活性，适用于预防或治疗需要抑制LPA生理活性的疾病，例如涉及LPA受体的疾病。
• NOVEL AZOLE COMPOUND
  申请人：YAMAMOTO Takashi

  公开号：US20130041000A1

  公开（公告）日：2013-02-14

  Azole compounds represented by formula I: wherein ring A is isoxazole and the like, R1 is a substituted or unsubstituted aryl group and the like, R2 is a hydrogen atom and the like, and R3 is a substituted or unsubstituted alkyl group and the like, and pharmaceutically acceptable salts thereof inhibit the physiological activity of lysophosphatidic acid (LPA), and are useful as for the prophylaxis or treatment of diseases in which inhibition of the physiological activity of LPA is useful for the prophylaxis or treatment thereof, such as diseases involving the LPA receptor.

  公式I所代表的氮唑化合物，其中环A是异噁唑等，R1是取代或未取代的芳基基团等，R2是氢原子等，R3是取代或未取代的烷基基团等，以及其药学上可接受的盐，能够抑制溶血磷脂酸（LPA）的生理活性，可用于预防或治疗需要抑制LPA生理活性的疾病，例如涉及LPA受体的疾病。
• Schulze, Klaus; Richter, Christian; Reimers, Frank, Zeitschrift fur Chemie, 1988, vol. 28, # 10, p. 363
  作者：Schulze, Klaus、Richter, Christian、Reimers, Frank

  DOI：——

  日期：——
• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：Buckman Brad O.

  公开号：US20130072449A1

  公开（公告）日：2013-03-21

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.